Business Description
Consun Pharmaceutical Group Ltd
ISIN : KYG2524A1031
Total Employee Number:
3,115Compare
Compare
Traded in other countries / regions
01681.Hong KongC1P.GermanyCPHGF.USA Index Membership
Hong Kong Stock Connect IPO Date
2013-12-19Description
Consun Pharmaceutical Group Ltd is a biotechnology company with a modern pharmaceutical enterprise that integrates R&D, production, and marketing. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Company derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 18.33 | |||||
Equity-to-Asset | 0.71 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | 0.18 | |||||
Interest Coverage | 264.62 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 6.94 | |||||
Beneish M-Score | -2.18 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.2 | |||||
3-Year EBITDA Growth Rate | 11.7 | |||||
3-Year EPS without NRI Growth Rate | 13 | |||||
3-Year FCF Growth Rate | 5.4 | |||||
3-Year Book Growth Rate | 11.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 12.9 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 12.85 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 84.27 | |||||
9-Day RSI | 75.64 | |||||
14-Day RSI | 69.15 | |||||
3-1 Month Momentum % | -7.53 | |||||
6-1 Month Momentum % | -25.82 | |||||
12-1 Month Momentum % | -7.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.22 | |||||
Quick Ratio | 3.03 | |||||
Cash Ratio | 2.73 | |||||
Days Inventory | 136.11 | |||||
Days Sales Outstanding | 27.58 | |||||
Days Payable | 48.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 5.89 | |||||
Dividend Payout Ratio | 0.46 | |||||
3-Year Dividend Growth Rate | 49.5 | |||||
Forward Dividend Yield % | 6.45 | |||||
5-Year Yield-on-Cost % | 20.8 | |||||
3-Year Average Share Buyback Ratio | -1.4 | |||||
Shareholder Yield % | 7.54 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 78.05 | |||||
Operating Margin % | 33.73 | |||||
Net Margin % | 31.55 | |||||
EBITDA Margin % | 35.14 | |||||
FCF Margin % | 33.47 | |||||
OCF Margin % | 35.48 | |||||
ROE % | 25.15 | |||||
ROA % | 17.79 | |||||
ROIC % | 43.48 | |||||
3-Year ROIIC % | 73 | |||||
ROC (Joel Greenblatt) % | 137.65 | |||||
ROCE % | 25.6 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 9.96 | |||||
Forward PE Ratio | 8.01 | |||||
PE Ratio without NRI | 9.98 | |||||
Shiller PE Ratio | 17.24 | |||||
Price-to-Owner-Earnings | 9.21 | |||||
PEG Ratio | 1.04 | |||||
PS Ratio | 3.14 | |||||
PB Ratio | 2.31 | |||||
Price-to-Tangible-Book | 2.52 | |||||
Price-to-Free-Cash-Flow | 9.37 | |||||
Price-to-Operating-Cash-Flow | 8.84 | |||||
EV-to-EBIT | 4.78 | |||||
EV-to-EBITDA | 4.78 | |||||
EV-to-Revenue | 1.68 | |||||
EV-to-FCF | 5.02 | |||||
Price-to-GF-Value | 1.61 | |||||
Price-to-Projected-FCF | 0.7 | |||||
Price-to-DCF (Earnings Based) | 0.38 | |||||
Price-to-DCF (FCF Based) | 0.3 | |||||
Price-to-Median-PS-Value | 1.58 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.04 | |||||
Price-to-Graham-Number | 1.06 | |||||
| Price-to-Net-Current-Asset-Value | 3.84 | |||||
| Price-to-Net-Cash | 5.16 | |||||
Earnings Yield (Greenblatt) % | 20.92 | |||||
FCF Yield % | 10.87 | |||||
Forward Rate of Return (Yacktman) % | 17.6 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Consun Pharmaceutical Group Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 3,756.938 | ||
| EPS (TTM) (HK$) | 1.385 | ||
| Beta | 0.9347 | ||
| 3-Year Sharpe Ratio | 0.89 | ||
| 3-Year Sortino Ratio | 1.67 | ||
| Volatility % | 35.27 | ||
| 14-Day RSI | 69.15 | ||
| 14-Day ATR (HK$) | 0.512985 | ||
| 20-Day SMA (HK$) | 13.74 | ||
| 12-1 Month Momentum % | -7.21 | ||
| 52-Week Range (HK$) | 12.31 - 19.35 | ||
| Shares Outstanding (Mil) | 839.05 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Consun Pharmaceutical Group Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Consun Pharmaceutical Group Ltd Stock Events
| Event | Date | Price (HK$) | ||
|---|---|---|---|---|
| HKD 0.380000 Cash Dividend | 2026-09-08 | In 12 days | ||
| HKD 0.400000 Cash Dividend | 2026-06-09 | 14.40 (-0.14%) | ||
| HKD 0.330000 Cash Dividend | 2025-09-04 | 15.48 (+3.89%) | ||
| HKD 0.300000 Cash Dividend | 2025-06-10 | 11.56 (-1.20%) | ||
| HKD 0.300000 Cash Dividend | 2024-09-05 | 5.67 (+0.18%) |
Show
Entries
Consun Pharmaceutical Group Ltd Frequently Asked Questions
What is Consun Pharmaceutical Group Ltd(HKSE:01681)'s stock price today?
The current price of HKSE:01681 is HK$13.79. The 52 week high of HKSE:01681 is HK$19.35 and 52 week low is HK$12.31.
When is next earnings date of Consun Pharmaceutical Group Ltd(HKSE:01681)?
The next earnings date of Consun Pharmaceutical Group Ltd(HKSE:01681) is .
Does Consun Pharmaceutical Group Ltd(HKSE:01681) pay dividends? If so, how much?
The Dividend Yield %  of Consun Pharmaceutical Group Ltd(HKSE:01681) is 5.89% (As of Today), Highest Dividend Payout Ratio of Consun Pharmaceutical Group Ltd(HKSE:01681) was 4.71. The lowest was 0.15. And the median was 0.36. The  Forward Dividend Yield % of Consun Pharmaceutical Group Ltd(HKSE:01681) is 6.45%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Consun Pharmaceutical Group Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers